本期为您推荐Thieme医学期刊Thrombosis and Haemostasis在2019年被引次数排名前五的论文。免费阅读或下载本期推荐论文PDF版，关注微信后回复“401”即可。
Kang et al.
| Fig. 1 Characteristics of the seven randomized clinical trials (RCTs) included in the present analysis.
Jung et al.
| Fig. 2 Flowchart of study population. AF, atrial fibrillation; HCM, hypertrophic cardiomyopathy; NVAF, non-valvular atrial fibrillation; OAC, oral anticoagulant.
Yamakawa et al.
| Fig. 3 Forest plot of the comparison: rhTM versus control: all-cause mortality at 28 days. CI, confidence interval; M-H, Mantel-Haenszel; rhTM, recombinant human thrombomodulin.
Adamkewicz et al.
| Fig. 2 The effect of emicizumab on aPTT and thrombin time. aPTT (A) and thrombin time (B) were determined in three haemophilia A samples (solid lines, open symbols) and two control normal plasma samples (dashed lines, closed symbols), which were spiked with increasing concentrations of emicizumab. aPTT, activated partial thromboplastin time; TT, thrombin time.
Therapeutic Targeting of Neutrophil Extracellular Traps in Atherogenic Inflammation
Van Avondt et al.
| Fig. 2 The involvement of neutrophil extracellular traps (NETs) during the different stages of atherosclerosis and its complications.
Thrombosis and Haemostasis
Issues per year : 12
Volume : 120
Year : 2020
ISSN : 0340-6245
影响因子：4.733
Thrombosis and Haemostasis 致力于发表血栓形成和止血、血管生物学和医学、炎症和感染、血小板和白细胞生物学等领域（从遗传、分子和细胞研究、诊断、治疗和预防研究到高水平的转化和临床研究）的最新成果和高质量的基础、转化和临床研究报告。本刊出版有立场与指导性的论文、前沿论文、专家分析和评论，以及涉及该领域最新发展和关键主题的专题。
